The Future Looks Bright For Orphan Drugs
This article was originally published in Scrip
Executive Summary
Designed to encourage clinical development in medical diseases that affect fewer than 200,000 people in the US, an orphan drug designation provides assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity.